Short answer
Cogent Biosciences, Inc. (COGT) filed an 8-K current report with the SEC on August 10, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
Cogent Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release dated August 10, 2026 contains the substantive operating and financial details
- Exhibit 99.1 incorporated into the 8-K as the investor reference point
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 loss $96.4M versus $73.5M; operating expenses rose to $102.6M amid clinical and commercial launch investment
- Cash $792.3M plus $73.6M ATM proceeds, supporting operations into late 2028 through potential approvals and early launch activities
- Bezuclastinib PDUFA dates: November 30 for GIST and December 30 for NonAdvSM, creating near-term regulatory catalysts
- GIST PEAK trial cut progression or death risk 50%; median PFS 16.5 months versus 9.2 months with sunitinib
- AdvSM APEX data showed 65% ORR among 68 evaluable patients, with 57% achieving CR, CRh or PR
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cogent Biosciences, Inc. 8-K filings
Get the next COGT 8-K as it lands
Follow COGT for push alerts, or ask the research agent what this filing means.